- Home
- VERA vs PTGX Comparison
VERA vs PTGX Comparison
Compare VERA & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERA
- PTGX
- Stock Information
- Founded
- VERA 2016
- PTGX 2006
- Country
- VERA United States
- PTGX United States
- Employees
- VERA N/A
- PTGX N/A
- Industry
- VERA Biotechnology: Pharmaceutical Preparations
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- VERA Health Care
- PTGX Health Care
- Exchange
- VERA Nasdaq
- PTGX Nasdaq
- Market Cap
- VERA 2.5B
- PTGX 2.8B
- IPO Year
- VERA 2021
- PTGX 2016
- Fundamental
- Price
- VERA $42.01
- PTGX $47.91
- Analyst Decision
- VERA Strong Buy
- PTGX Strong Buy
- Analyst Count
- VERA 9
- PTGX 7
- Target Price
- VERA $53.56
- PTGX $52.83
- AVG Volume (30 Days)
- VERA 683.6K
- PTGX 450.1K
- Earning Date
- VERA 11-07-2024
- PTGX 11-08-2024
- Dividend Yield
- VERA N/A
- PTGX N/A
- EPS Growth
- VERA N/A
- PTGX N/A
- EPS
- VERA N/A
- PTGX 2.75
- Revenue
- VERA N/A
- PTGX $319,120,000.00
- Revenue This Year
- VERA N/A
- PTGX $400.33
- Revenue Next Year
- VERA N/A
- PTGX N/A
- P/E Ratio
- VERA N/A
- PTGX $17.54
- Revenue Growth
- VERA N/A
- PTGX 125.73
- 52 Week Low
- VERA $9.68
- PTGX $13.76
- 52 Week High
- VERA $50.78
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- VERA 52.57
- PTGX 60.40
- Support Level
- VERA $39.22
- PTGX $45.33
- Resistance Level
- VERA $50.00
- PTGX $48.89
- Average True Range (ATR)
- VERA 2.41
- PTGX 1.28
- MACD
- VERA 0.24
- PTGX 0.11
- Stochastic Oscillator
- VERA 28.53
- PTGX 77.11
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.